Sotera Health Company reported strong Q2 CY2026 results, exceeding analyst expectations for revenue, adjusted EPS, and adjusted EBITDA, driven by growth in Sterigenics and Nordion, and improved customer engagement at Nelson Labs. Management raised full-year guidance, attributing confidence to new capacity and customer onboarding. Key analyst questions focused on growth drivers, CEO priorities, differentiation, guidance confidence, and a litigation/outsourcing update, all addressed positively by the leadership team.
Yahoo Finance
Original source
yahoo finance
Check live status on DownRightNow

